Eli Lilly Links Zepbound to Lower Healthcare Costs
Zepbound Use Associated With Lower Healthcare Costs INDIANAPOLIS, Aug. 26, 2026 — Eli Lilly and Company announced new real-world...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Zepbound Use Associated With Lower Healthcare Costs INDIANAPOLIS, Aug. 26, 2026 — Eli Lilly and Company announced new real-world...
BOCA RATON, Fla., June 19, 2026 5W AI Communications has released its Pharma / Rx AI Visibility Index 2026,...
INDIANAPOLIS, United States, June 10, 2026 Eli Lilly and Company has launched a nationwide awareness campaign featuring NBA legend...
INDIANAPOLIS, May 12, 2026 Eli Lilly and Company has reported positive results from two major late-phase obesity trials showing...
LEBANON, Indiana, United States – May 6, 2026 Eli Lilly and Company has announced an additional $4.5 billion investment...
Indianapolis, USA | March 28, 2026 Phase 3b Study Demonstrates Superior Clinical Outcomes Eli Lilly and Company has announced...
